DCA Vantage® AnalyzerDrive diabetic patient compliance with trusted, clinically proven results
Provide the clinical confidence your patients deserve. The DCA Vantage® Analyzer helps you monitor glycemic control and detect early kidney disease in environments ranging from the physician’s office to remote, point-of-care coordinated sites in hospitals and multisite practices. Meet lab-quality testing standards with an analyzer that speeds and simplifies diabetes tests and delivers accurate,1 clinically relevant results shown to improve decision-making,2,3 patient compliance, and outcomes.4
- Manage diabetes patients more effectively
- Improve workflow in office or clinic
- Simplify management of diabetes testing in decentralized settings
- One of just two HbA1c analyzers that meet NGSP performance criteria1
- Used by three out of four physicians who perform HbA1c testing in their office5
Características y Beneficios
Monitor glycemic control and diabetes complications using an analyzer designed to make consultations easier. Fast, actionable test results enable you to determine the effectiveness of a treatment plan, make therapeutic adjustments with confidence, and be more certain whether patients are complying with your recommendations.
Monitor glycemic control
- HbA1c from a small (1 µL) whole blood sample in 6 minutes
- Flexible reporting of HbA1c% (NGSP, JDS, and Mono-S units) and IFCC (mmol/mol)
- Reporting of HbA1c results as Estimated Average Glucose values* in the same units (mg/dL) that patients’ home glucose meters display
- HbA1c patient trending graphs can be viewed or printed
Detect early kidney disease
- Albumin, Creatinine, and Albumin-to-Creatinine (A:C) ratio from a urine specimen in 7 minutes to report a quantitative protein status with automatic creatinine adjustment
- Onboard GFR calculator indexes kidney function
Improve workflow in the office or clinic
- Self-contained cartridges facilitate easy, walkaway operation after sample loading
- No sample or reagent preparation required
- Bar-code scanner for safer and faster patient/operator ID entry
- Review results on-screen or generate a hard copy report to minimize transcription errors in the office
- Convenient local storage of up to 4,000 onboard records with powerful sorting capabilities
- Automatically upload results to a PC via a USB flash drive to reduce manual logging and save time
- Minimal maintenance requirements with automatic reminders to alert you when maintenance is due
Simplify management of diabetes testing in decentralized settings
- Customizable security access modes support up to 1,000 operators, protect patient information, and prevent operation by unauthorized users
- POCT1-A2 communication protocol streamlines data transfer for easy connectivity and fast, two-way communication to LIS/HIS, RAPIDComm® System, or other third-party POC data management systems
- Automatically upload results and QC information to LIS/HIS to reduce manual logging and save time
- Take testing oversight to the next level with RAPIDComm Data Management System to remotely manage multiple analyzers and operators to enhance compliance and improve risk management. POC coordinators can standardize test procedures, enforce QC protocols, control access privileges, define operator recertification requirements, and more. Customized alerts, reports, and audit trails ensure peace of mind and simplify accreditation and inspections
ensayos
Formulas for Calculated Results
% HbA1c = (HbA1c/Total Hemoglobin) x 100
eAG* mg/dL = (28.7 x HbA1C) – 46.7
eAG* mmol/L = (1.59 x HbA1C) – 2.59
GFR = 186 x (plasma creatinine mg/dL)-1.154 x (patient age years)-0.203 x (0.742 if female patient) x (1.210 if African American patient)
Formulas for Dual Reporting From IFCC to % HbA1c
NGSP = (0.09148 x IFCC) + 2.152
JDS = (0.09274 x IFCC) +1.724
Mono-S = (0.09890 x IFCC) + 0.884
Formulas for Dual Reporting From % HbA1c to IFCC mmol/mol
IFCC = (10.93 x NGSP) – 23.50
IFCC = (10.78 x JDS) – 18.59
IFCC = (10.11 x Mono-S) – 8.94
Especificaciones Técnicas
¿Fue útil esta información?
References
1 Lenters-Westra E, Slingerland RJ. Clin Chem 2010;56(1):44.
2 Thaler LM, et al. Diabetes Care 1999;22:1415-21.
3 Miller CD, et al. Diabetes Care 2003;26:1158-63.
4 Cagliero E, et al. Diabetes Care 1999;22:1785-9.
5 GHX Market Intelligence, market data report. 4Q 2012 Report.
* Not available in the U.S.
The products/features (mentioned herein) are not commercially available in all countries. Due to regulatory reasons their future availability cannot be guaranteed. Please contact your local Siemens Healthineers organization for further details.